Radiotherapy-free neoadjuvant strategy using sintilimab plus XELOX in locally advanced rectal cancer: A single-arm phase II trial

doi:10.3748/wjg.117924

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 26

This Article

(30)

(42)

(0)

(22)

(454)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jul 14, 2026; 32(26): 117924
Published online Jul 14, 2026. doi: 10.3748/wjg.117924

Table 2 Treatment outcomes and surgical parameters, n (%)

Characteristic	All patients (n = 41)
Clinical T stage after treatment
cT0	4 (9.8)
cT1	2 (4.9)
cT2	8 (19.5)
cT3	23 (56.0)
cT4a	4 (9.8)
Clinical N stage after treatment
cN0	11 (26.8)
cN1	17 (41.5)
cN2	13 (31.7)
NAR
Less than 8	22 (53.7)
8 to 16	10 (24.4)
Not less than 16	9 (21.9)
ORR	35 (85.4)
DCR	41 (100)
CR	4 (9.8)
PR	31 (75.6)
SD	6 (14.6)
PD	0 (0)
Reduced TMN stage
T stage reduction	17 (41.5)
N stage reduction	17 (41.5)
TN stage reduction	10 (24.4)
Pathological T stage
ypT0	11 (26.8)
ypTis	1 (2.4)
ypT1	7 (17.1)
ypT2	10 (24.4)
ypT3	10 (24.4)
ypT4	2 (4.9)
Pathological N stage
ypN0	30 (73.2)
ypN1	9 (21.9)
ypN2	2 (4.9)
PCR	11 (26.8)
TRG classification
TRG 0	11 (26.8)
TRG 1	8 (19.5)
TRG 2	10 (24.4)
TRG 3	12 (29.3)
MPR	19 (46.3)
Resection range
R0	41 (100)
R1	0 (0)

NAR: Neoadjuvant rectal; ORR: Objective response rate; DCR: Disease control rate; CR: Complete remission; PR: Partial response rate; SD: Disease stability rate; DP: Disease progression; PCR: Pathological complete response rate; MPR: Major pathological remission rate; TRG: Tumor regression grade.

Full Size Table

Citation: Qiang WD, Wei Q, Yang B, Chen WJ, Lin CQ, Li YX. Radiotherapy-free neoadjuvant strategy using sintilimab plus XELOX in locally advanced rectal cancer: A single-arm phase II trial. World J Gastroenterol 2026; 32(26): 117924
URL: https://www.wjgnet.com/1007-9327/full/v32/i26/117924.htm
DOI: https://dx.doi.org/10.3748/wjg.117924

Qiang WD, Wei Q, Yang B, Chen WJ, Lin CQ, Li YX. Radiotherapy-free neoadjuvant strategy using sintilimab plus XELOX in locally advanced rectal cancer: A single-arm phase II trial. World J Gastroenterol 2026; 32(26): 117924 [DOI: 10.3748/wjg.117924]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.